Antimicrobial effects of virgin coconut oil and its medium-chain fatty acids on clostridium difficile

Journal of Medicinal Food

Volumn 16, Issue 12, 2013, Pages 1079-1085

  Shilling, Michael ^a   Matt, Laurie ^b   Rubin, Evelyn ^b   Visitacion, Mark Paul ^b   Haller, Nairmeen A ^b,c   Grey, Scott F ^a   Woolverton, Christopher J ^a  

^a KENT STATE UNIVERSITY   (United States)

^b AKRON GENERAL MEDICAL CENTER   (United States)

^c Northeast Ohio Medical University   (United States)

Author keywords

Clostridium difficile; Coconut oil; Fatty acid; Growth inhibition

Indexed keywords

COCONUT OIL; DECANOIC ACID; FATTY ACID; LAURIC ACID; LIPID; MEDIUM CHAIN FATTY ACID; OCTANOIC ACID; UNCLASSIFIED DRUG; VIRGIN COCONUT OIL;

ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL CELL; BACTERIAL MEMBRANE; BACTERIAL STRAIN; CELL MEMBRANE; CLOSTRIDIUM DIFFICILE; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOPLASM; GROWTH INHIBITION; IN VITRO STUDY; INTESTINE; LIPID COMPOSITION; LIPOLYSIS; NONHUMAN; PH; PRIORITY JOURNAL; REDUCTION; STAINING; TRANSMISSION ELECTRON MICROSCOPY;

ANTI-BACTERIAL AGENTS; CAPRYLATES; CLOSTRIDIUM DIFFICILE; COLONY COUNT, MICROBIAL; DECANOIC ACIDS; DRUG RESISTANCE, BACTERIAL; FATTY ACIDS; LAURIC ACIDS; METRONIDAZOLE; MICROBIAL VIABILITY; MICROSCOPY, ELECTRON, TRANSMISSION; PLANT OILS;

EID: 84890481784     PISSN: 1096620X     EISSN: 15577600     Source Type: Journal    
DOI: 10.1089/jmf.2012.0303     Document Type: Article

References (39)

1. LaMont JT: Epidemiology, microbiology, and pathophysiology of Clostridium difficile infection in adults. In: UpToDate (Basow DS, ed.). Waltham, MA, 2011.
2. Poutanen SM, Simor AE: Clostridium difficile-associated diarrhea in adults. CMAJ 2004;171: 51-58.
3. O'Brien JA, Lahue BJ, J Jaime Caro M, Davidson DM: The emerging infectious challenge of Clostridium difficile - associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol 2007;28: 1219-1227.
4. Curry SR, Marsh JW, Muto CA, et al.: tcdC genotypes associated with severe TcdC truncation in an epidemic clone and other strains of Clostridium difficile. J Clin Microbiol 2007;45: 215.
5. McFarland LV, Elmer GW, Surawicz CM: Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002;97: 1769-1775.
6. Layton BA ML, Gerding DN, Liedtke LA, Strausbaugh LJ: Patterns of Clostridium difficile Disease: a Report from Infectious Diseases Physicians, Abstracts 563. Infect Dis Soc Am 2004.
7. Centers for Disease Control and Prevention: Information about a new strain of Clostridium difficile. (Online) 2005. www.cdc.gov/HAI/organisms/cdiff/ cdiff-current-strain.html (accessed June 2009).
8. Hitt E: FDA approves fidaxomicin for the treatment of C. difficile. (Online) 2011. www.medscape.com/viewarticle/743582 (accessed June 2009).
9. McDonald LC, Killgore GE, Thompson A, et al.: An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005;353: 2433-2441.
10. Kabara JJ, Swieczkowski DM, Conley AJ, Truant JP: Fatty acids and derivatives as antimicrobial agents. Antimicrob Agents Chemother 1972;2: 23-28.
11. Kabara JJ: Health oils from the tree of life. Nutritional and health aspects of coconut oil. Ind Coconut J 2000;31: 2-8.
12. Skřivanová E, Marounek M, Dlouha G, Kaňka J: Susceptibility of Clostridium perfringens to C2-C18 fatty acids. Lett Appl Microbiol 2005;41: 77-81.
13. Skrivanova E, Marounek M, Benda V, Brezina P: Susceptibility of Escherichia coli, Salmonella sp. and Clostridium perfringens to organic acids and monolaurin. Vet Med 2006;51: 81-88.
14. Bergsson G, Steingrimsson O, Thormar H: In vitro susceptibilities of Neisseria gonorrhoeae to fatty acids and monoglycerides. Antimicrob Agents Chemother 1999;43: 2790.
15. Bergsson G, Arnfinnsson J, Karlsson SM, Steingrimsson O, Thormar H: In vitro inactivation of Chlamydia trachomatis by fatty acids and monoglycerides. Antimicrob Agents Chemother 1998;42: 2290-2294.
16. Bergsson G, Arnfinnsson J, Steingrimsson O, Thormar H: In vitro killing of Candida albicans by fatty acids and monoglycerides. Antimicrob Agents Chemother 2001;45: 3209.
17. Ogbolu DO, Oni AA, Daini OA, Oloko AP: In vitro antimicrobial properties of coconut oil on Candida species in Ibadan, Nigeria. J Med Food 2007;10: 384-387.
18. Dayrit CS: Coconut oil in health and disease: its and monolaurin's potential as cure for HIV/AIDS. Ind Coconut J (Cochin) 2000;31: 19-24.
19. Marina AM, Che Man YB, Nazimah SAH, Amin I: Chemical properties of virgin coconut oil. J Am Oil Chem Soc 2009;86: 301-307.
20. Laureles LR, Rodriguez FM, Reaño CE, et al.: Variability in fatty acid and triacylglycerol composition of the oil of coconut (Cocos nucifera L.) hybrids and their parentals. J Agric Food Chem 2002;50: 1581-1586.
21. Mattson F, Volpenhein R: The use of pancreatic lipase for determining the distribution of fatty acids in partial and complete glycerides. J Lipid Res 1961;2: 58-62.
22. Bergsson G, Arnfinnsson J, Steingrímsson Ó, Thormar H: Killing of Gram positive cocci by fatty acids and monoglycerides. APMIS 2001;109: 670-678.
23. Thormar H, Isaacs C, Brown H, Barshatzky M, Pessolano T: Inactivation of enveloped viruses and killing of cells by fatty acids and monoglycerides. Antimicrob Agents Chemother 1987; 31: 27-31.
24. Wang LL, Yang BK, Parkin KL, Johnson EA: Inhibition of Listeria monocytogenes by monoacylglycerols synthesized from coconut oil and milkfat by lipase-catalyzed glycerolysis. J Agric Food Chem 1993;41: 1000-1005.
25. Bergsson G: In vitro inactivation of Chlamydia trachomatis by fatty acids and monoglycerides. Antimicrob Agents Chemother 1998;42: 2290.
26. Pye G, Evans D, Ledingham S, Hardcastle J: Gastrointestinal intraluminal pH in normal subjects and those with colorectal adenoma or carcinoma. Gut 1990;31: 1355-1357.
27. Kabara J, Vrable R, Jie MLK: Antimicrobial lipids: natural and synthetic fatty acids and monoglycerides. Lipids 1977;12: 753-759.
28. Dumitriu S, Chornet E, Vidal PF, Moresoli C: Polyionic hydrogels as support for immobilization of lipase. Biotechnol Tech 1995;9: 833-836.
29. R Development Core Team: R: A Language and Environment for Statistical Computing. R Foundation for Stastical Computing, Vienna, Austria, 2011.
30. Mendis S, Webber D, Norrving B, et al.: Avoiding Heart Attacks and Strokes: Don't Be a Victim - Protect Yourself. World Health Organization, Geneva, 2005.
31. Kaunitz H, Dayrit CS: Coconut oil consumption and coronary heart disease. Philipp J Coconut Stud 1992;17: 165-171.
32. Nevin KG, Rajamohan T: Beneficial effects of virgin coconut oil on lipid parameters and in vitro LDL oxidation. Clin Biochem 2004;37: 830-835.
33. Bartolotta S, Garci CC, Candurra NA, Damonte EB: Effect of fatty acids on arenavirus replication: inhibition of virus production by lauric acid. Arch Virol 2001;146: 777-790.
34. Jensen RG, Clark RM, deJong FA, et al.: The lipolytic triad human lingual, breast milk, and pancreatic lipases: physiological implications of their characteristics in digestion of dietary fats. J Pediatr Gastroenterol Nutr 1982;1: 243.
35. Wilson KH, Kennedy MJ, Fekety FR: Use of sodium taurocholate to enhance spore recovery on a medium selective for Clostridium difficile. J Clin Microbiol 1982;15: 443.
36. George W, Sutter V, Citron D, Finegold S: Selective and differential medium for isolation of Clostridium difficile. J Clin Microbiol 1979;9: 214-219.
37. Ghosh S, Bhattacharyya DK: Medium-chain fatty acid-rich glycerides by chemical and lipase-catalyzed polyester-monoester interchange reaction. J Am Oil Chem Soc 1997;74: 593-595.
38. Beare-Rogers J, Dieffenbacher A, Holm J: Lexicon of lipid nutrition. Pure Appl Chem 2001;73: 685-744.
39. Enig MG: Lauric oils as antimicrobial agents: theory of effect, scientific rationale, and dietary applications as adjunct nutritional support for HIV-infected individuals. In: Nutrients and Foods in AIDS (Watson RR, ed.). CRC Press, Boca Raton, FL, USA, 1998, pp. 81-97.